MedDataX Logo

Seroquel Long-Term NIS for Schizophrenia Patients

NCT ID: NCT00523783

Last Updated: 2008-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-05-31

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the efficacy of 24-week treatment with quetiapine in patients with schizophrenia or schizoaffective disorder

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Schizoaffective Disorder

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Schizophrenia Schizoaffective quetiapine long-term efficacy Naturalistic Observational

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent
* The patient suffers from schizophrenia or schizoaffective disorder according to DSM-IV-TR
* The patient is between 18 and 65 years old(extremes included)
* On the basis of physical and neurological examination, medical history, the patient is, in the investigator's opinion, otherwise healthy
* If the subject is a female of childbearing potential, she must be not pregnant or breast-feeding and be using a reliable method of contraception. Reliable methods may include abstinence, hormonal contraceptives (eg,oral contraceptives or long-term injectable or implantable hormonal contraceptives), double-barrier methods (eg, condom and diaphragm, condom and foam, condom and sponge), intrauterine devices, and tubal ligation

Exclusion Criteria

* The patients who have known hypersensitivity to quetiapine
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joon-Woo Bahn

Role: STUDY_DIRECTOR

AstraZeneca Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Seoul, Dongdamoon-gu, South Korea

Site Status

Research Site

Seoul, Kangnam-gu, South Korea

Site Status

Research Site

Seoul, Songpa-gu, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-NKR-SER-2007/1

Identifier Type: -

Identifier Source: org_study_id